Previous 10 | Next 10 |
2023-03-15 16:39:47 ET Medical technology company Enovis ( NYSE: ENOV ) appointed CEO Matt Trerotola to the additional position of board chair, effective following the May 16 annual meeting of stockholders. Current Chair Mitchell Rales will retire on the same day...
Wilmington, March 15, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that CEO Matt Trerotola will assume the additional position of Chair of the Board, effective following the Company’s 2023 Annual ...
Wilmington, DE, March 03, 2023 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it will feature its next generation of medical technology at the upcoming American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting Marc...
Wilmington, DE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it has been recognized as one of America’s Greatest Workplaces for Diversity by Newsweek . The listing recognizes the best workplace...
Summary Enovis came up a little short with revenue and margins for both the fourth quarter of 2022 and guidance for 2023. The Reconstructive segment is performing well, with growth in U.S. hips, knees, and extremities that was well ahead of the group. The Prevention & Recovery b...
Enovis Corp (ENOV) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 ET Company Participants Derek Leckow - VP, IR Matthew Trerotola - CEO & Director Phillip Berry - CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities ...
Shares of Enovis ( NYSE: ENOV ) on Thursday fell as much as 11.9% to $54.27 after the company reported mixed Q4 results and provided disappointing FY 2023 adj. earnings guidance. ENOV earlier in the day posted Q4 adj. EPS of $0.72 which beat estimates by $0.06 . Revenue gr...
Enovis Corporation press release ( NYSE: ENOV ): Q4 Non-GAAP EPS of $0.72 beats by $0.06 . Revenue of $408.7M (+2.4% Y/Y) misses by $7.09M . Enovis’ fourth quarter net sales of $409 million grew 2% from the prior year, reflecting 5% organic growth offset by a 3%...
Wilmington, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. The Company will host an investor conference call a...
Enovis Corporation ( NYSE: ENOV ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is $0.66 (+11.9% Y/Y) and the consensus Revenue Estimate is $415.79M. Over the last 2 years, ENOV has beaten EPS estimate...
News, Short Squeeze, Breakout and More Instantly...
Enovis Corporation Company Name:
ENOV Stock Symbol:
NYSE Market:
Wilmington, DE, May 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Bank of America Healthcare Conference: Ben ...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
Strong start to the year with sales growth of 27% on a reported basis and strong adjusted margin expansion Reported first-quarter net loss from continuing operations of $1.32 per share with adjusted earnings per diluted share of $0.50 Wilmington, DE, May 02, 2024 (GLOBE NEWSWIRE...